Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 9/20 | 0.55 |
| ▸ | AXL | P30530 | 3/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | PLK4 | O00444 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | INSR | P06213 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | ROS1 | P08922 | 2/20 | 0.45 |
| ▸ | FER | P16591 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | MARK3 | P27448 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349543 | 1.00 | CDK8 (0.55) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL23655689 | 0.81 | CDK8 (0.56) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL4831501 | 0.78 | CDK8 (0.81) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL11968477 | 0.75 | CDK8 (0.55) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3348675 | 0.75 | CDK8 (0.55) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL926536 | 0.75 | CDK8 (0.55) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL297772 | 0.75 | CDK8 (0.55) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL294106 | 0.75 | CDK8 (0.55) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL294108 | 0.75 | CDK8 (0.55) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL16774589 | 0.75 | CDK8 (0.55) | CDK8AXLPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3565815-B1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS LTD (CN) | 2024-03-13 | — | — | EP | disclosed |
| CN-110177788-B | Compounds as BCL-2 selective apoptosis inducers | 重庆复创医药研究有限公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-3954679-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-11053239-B2 | Compounds as BLC-2-selective apoptosis-inducing agents | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| EP-3144292-B1 | 2,3,4,6-TETRA-SUBSTITUTED BENZENE-1,5-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20190345156-A1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
| EP-2925757-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| EP-2791130-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8067434-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | PLEXXIKON INC | 2010-12-23 | — | — | US | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345156-A1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | BCL2, BAX, BCL2L1 | CDK8 504/4885AXL 4683/4885PIK3CD 2423/4885 |
| US-11053239-B2 | Compounds as BLC-2-selective apoptosis-inducing agents | BCL2, BAX, BAD | CDK8 288/4885AXL 4732/4885PIK3CD 1587/4885 |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | RET, GFRA3, GFRA1 | CDK8 1633/4885AXL 38/4885PIK3CD 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.